Dominari Holdings Inc. (DOMH)
- Previous Close
2.7100 - Open
2.7100 - Bid --
- Ask --
- Day's Range
2.6000 - 2.7600 - 52 Week Range
1.7600 - 3.4600 - Volume
16,309 - Avg. Volume
12,647 - Market Cap (intraday)
16.024M - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-4.3800 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date May 12, 1980
- 1y Target Est
--
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
www.aikidopharma.comRecent News: DOMH
Performance Overview: DOMH
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DOMH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DOMH
Valuation Measures
Market Cap
16.02M
Enterprise Value
3.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.92
Price/Book (mrq)
0.30
Enterprise Value/Revenue
1.52
Enterprise Value/EBITDA
-0.14
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.08%
Return on Equity (ttm)
-36.12%
Revenue (ttm)
2.04M
Net Income Avi to Common (ttm)
-22.88M
Diluted EPS (ttm)
-4.3800
Balance Sheet and Cash Flow
Total Cash (mrq)
16.38M
Total Debt/Equity (mrq)
6.52%
Levered Free Cash Flow (ttm)
-14.39M
Research Analysis: DOMH
Company Insights: DOMH
DOMH does not have Company Insights